Scientific analyses fortified by interpretations of immunodeficiency diseases as ‘experiments of nature’ have revealed the specific immune systems to be comprised of T cells subserving cell-mediated immunities plus B cells and plasma cells which produce and secrete antibodies. These two separate cellular systems regularly interact with each other to produce a coordinated defense which permits mammals to live within a sea of microorganisms that threaten the integrity and the survival of individuals. We have shown that bone marrow transplantation (BMT) can be used as a form of cellular engineering to construct or reconstruct the immune systems and cure otherwise fatal severe combined immunodeficiency. When severe aplastic anemia complicated the first BMT which was performed to cure a fatal severe combined immunodeficiency, a second BMT cured for the first time a complicating severe aplastic anemia. Subsequently, BMT has been used effectively to treat some 75 otherwise fatal diseases such as resistant leukemias, lymphomas, inborn errors of metabolism, and genetic anomalies of the hematopoietic development such as sickle cell anemia, thalassemia, congenital neutropenias, and many other diseases. More recently, we have employed BMT in mice both to cure and cause autoimmunities, and, together, these experiments showed that autoimmunities actually reside in the hematopoietic stem cells. We have also found that mixed BMT or mixed hematopoietic stem cell transplantation (HSCT) can be used to prevent and cure the most complex autoimmunities such as those occurring in BXSB mice and in (NZW × BXSB)F1 W/BF1 mice. Untreated, the former develop fulminating lethal glomerulonephritis plus numerous humoral autoimmunities. Mice of the (W/B)F1 strain develop autoimmune thrombocytopenic purpura, coronary vascular disease with myocardial infarction, glomerulonephritis, and numerous autoantibodies. All of these abnormalities are prevented or cured by mixed syngeneic (autoimmune) plus allogeneic (normal healthy) BMT or mixed peripheral blood HSCT. Thus, the most complex autoimmune diseases can be prevented or cured in experimental animals by mixed syngeneic plus allogeneic BMT or HSCT which produce stable mixed chimerism as a form of cellular engineering.

Keywords:
Bone marrow transplantation, T cell depletion, Total body irradiation, Stable mixed chimerism, Hematopoietic stem cells, Hematopoietic stem cell transplantation, Autoimmune diseases, treatment/prevention, Mixed allogeneic plus syngeneic bone marrow transplantation/hematopoietic stem cell transplantation, Transdifferentiation
1.
Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone-marrow transplantation (first of two parts). N Engl J Med 1975;292:832–843.
2.
Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone-marrow transplantation (second of two parts). N Engl J Med 1975;292:895–902.
3.
Thomas E: Landmarks in the development of hematopoietic cell transplantation. World J Surg 2000;24:815–818.
4.
Gatti RA, Meuwissen HF, Allen HD, Hong R, Good RA: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;ii:1366–1369.
5.
Good RA, Meuwissen HF, Hong R, Gatti RA: Successful marrow transplantation for correction of immunological deficit in lymphopenic agammaglobulinemia and treatment of immunologically induced pancytopenia. Exp Hematol 1969;19:4–10.
6.
Good RA, Meuwissen HJ, Hong R, Gatti RA: Bone marrow transplantation: Correction of immune deficit in lymphopenic immunologic deficiency and correction of an immunologically induced pancytopenia. Trans Assoc Am Physicians 1969;82:278–285.
7.
Good RA: Immunologic reconstitution: The achievement and its meaning. Hosp Pract 1969;4:41–47.
8.
Good RA: Progress toward a cellular engineering (Lasker Award Lecture). JAMA 1970;214:1289–1300.
9.
Gatti RA, Good RA: Follow-up of correction of severe dual system immunodeficiency with bone marrow transplantation. J Pediatr 1971;79:475–479.
10.
Good RA: Bone marrow transplantation: Cellular engineering to correct primary immunodeficiency, aregenerative anemia and pancytopenia; in Bergsma D, Good RA, Finstad J (eds): Immunodeficiency in Man and Animals. Sunderland, Sinauer, 1975, pp 377–379.
11.
Good RA: Marrow transplantation and stem cell transplantation in 1996 – the developmental perspective; in Ikehara S, Takaku F, Good RA (eds): Bone Marrow Transplantation – Basic and Clinical Studies. Proc Int Symp on Bone Marrow Transplantation – Basic and Clinical Studies, Tokyo. Tokyo, Springer, 1996, pp 277–301.
12.
Horowitz MM: Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000;37:30–42.
13.
Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP, Sanders J, Sullivan KM: Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998;91:3637–3645.
14.
Storb R, Yu C, Deeg HJ, Georges G, Kiem HP, Mcsweeney PA, Nash RA, Sandmaier BM, Sullivan KM, Wagner JL, Walters MC: Current and future preparative regimens for bone marrow transplantation in thalassemia. Ann NY Acad Sci 1998;850:276–287.
15.
Walters MC, Patience M, Leisenring W, Rogers ZR, Dinndorf P, Davies SC, Roberts IA, Yeager A, Kurtzberg J, Bunin N, Scott JP, Wall DA, Wayne AS, Wiley J, Darbyshire PJ, Mentzer WC, Smith FO, Sullivan KM: Collaborative multicenter investigation of marrow transplant for sickle cell disease: Current results and future directions. Biol Blood Marrow Transplant 1997;3:310–315.
16.
Krivit W, Shapiro EG: Bone marrow transplantation for storage diseases; in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Oxford, Blackwell, 1994, pp 883–893.
17.
Peters C, Shapiro EG, Krivit W: Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation. Pediatr Transplant 1998;2:250–253.
18.
Suenaga K, Kanda Y, Niiya H, et al: Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria. Exp Hematol 2001;29:639–642.
19.
Welte K, Boxer LA: Severe chronic neutropenia: Pathophysiology and therapy. Semin Hematol 1997;34:267–278.
20.
Good RA, Kapoor N, Reisner Y: Bone marrow transplantation – an expanding approach to treatment of many diseases. Cell Immunol 1983;82:36–54.
21.
Roos D, Curnutte J: Chronic granulomatous disease; in Ochs H, Smith C, Puck J (eds): Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, Oxford University Press, 1999, pp 353–374.
22.
Berendes H, Bridges RA, Good RA: Fatal granulomatous disease of childhood: Clinical study of a new syndrome. Minn Med 1957;40:309–312.
23.
Sackstein R, Jannssen WE, Elfenbein GJ: Bone marrow transplantation: Foundations of the 21st Century. Ann NY Acad Sci 1995:770.
24.
Onoé K, Fernandes G, Good RA: Humoral and cell-mediated immune responses in fully allogeneic bone marrow chimera in mice. J Exp Med 1980;151:115–132.
25.
Calne RY: Prope tolerance: A step in the search for tolerance in the clinic. World J Surg 2000;24:793–796.
26.
Starzl TE, Demetris AJ: Transplantation milestones: Viewed with one- and two-way paradigms of tolerance. JAMA 1995;273:876.
27.
Starzl TE: History of clinical transplantation. World J Surg 2000;24:759–782.
28.
Good RA, Zak SJ: Disturbances in gamma globulin synthesis as ‘experiments of nature’. Pediatrics 1956;18:109–149.
29.
Good RA: The Minnesota Scene: A crucial portal of entry to modern cellular immunology; in Champlin RE, Gale RP (eds): The Immunological Revolution: Facts and Witnesses. Boca Raton, University Press of Florida, 1993, pp 105–168.
30.
Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M: Haematopoietic chimera in man after allogeneiec (homologous) bone marrow transplantation. Br Med J 1963;ii:1633.
31.
Wang BY, Cherry, El-Badri NS, Good RA: Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation. Proc Natl Acad Sci USA 1997;94:12065–12069.
32.
Wang BY, Yamamoto Y, El-Badri NS, Good RA: Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice. Proc Natl Acad Sci USA 1999;96:3012–3016.
33.
Mizutani H, Engelman RW, Kinjoh K, Kurata Y, Ikehara S, Good RA: Prevention and induction of occlusive coronary vascular disease in autoimmune (W/B)F1 mice by haploidentical bone marrow transplantation: Possible role for anticardiolipin autoantibodies. Blood 1993;82:3091–3097.
34.
Kirzner RP, Engelman RW, Mizutani H, Specter S, Good RA: Prevention of coronary vascular disease by transplantation of T cell depleted bone marrow and hematopoietic stem cell preparation in autoimmune-prone W/BF1 mice. Biol Blood Marrow Transplant 2000;6:13–22.
35.
Burt RK, Marmont A, Schroeder J, Rosa R, Traynor AE: Intense suppression for systemic lupus – the role of hematopoietic stem cells. J Clin Immunol 2000;20:31–37.
36.
Yoshida S, Castles JJ, Gerswhin ME: The pathogenesis of autoimmunity in New Zealand mice. Semin Arthritis Rheum 1990;19:224–242.
37.
Sardiña EE, Sugiura K, Ikehara S, Good RA: Transplantation of WGA+ hematopoietic cells to prevent or induce systemic autoimmune disease. Proc Natl Acad Sci USA 1991;88:3218–3222.
38.
El-Badri NS, Wang BY, Steele A, Cherry, Marikar Y, Mizobe K, Good RA: Successful prevention of autoimmune disease by transplantation of adequate number of fully allogeneic hematopoietic stem cells. Transplantation 2000;70:870–877.
39.
Hang L, Izui S, Dixon F: (NZW × BXSB)F1 hybrid: A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 1981;154:216–221.
40.
Berden J, Hang L, McConahey P, Dixon F: Analysis of vascular lesions in murine SLE. I. Association with serologic abnormalities. J Immunol 1983;130:1699–1705.
41.
Jynouchi H, Kincade PW, Good RA, Fernandes GJ: Reciprocal transfer of abnormalities in clonable B lymphocytes and myeloid progenitors between NZB and DBA/2 mice. J Immunol 1981;127:1232–1238.
42.
Kincade PW, Lee G, Fernandes G, Moore MAS, Williams N, Good RA: Abnormalities in clonable B lymphocytes and myeloid progenitors in autoimmune NZB mice. Proc Natl Acad Sci USA 1979;76:3464–3468.
43.
Kotzin BL, Strober S: Reversal of NZB/NZW disease with total lymphoid irradiation. J Exp Med 1979;150:371–378.
44.
Warner NL, Moore MAS: Defects in hematopoietic differentiation in NZB and NZB mice. J Exp Med 1971;134:313–334.
45.
Ikehara S, Good RA, Nakamura T, Sekita K, Inoue S, Oo MM, Muso E, Ogawa K, Hamashima Y: Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 1985;82:2483–2487.
46.
Ikehara S: The prospects for BMT – from mouse to human; in Ikehara S, Takaku F, Good RA (eds): Bone Marrow Transplantation – Basic and Clinical Studies. Proc Int Symp on Bone Marrow Transplantation – Basic and Clinical Studies, Tokyo. Tokyo, Springer, 1996, pp 320–331.
47.
Good RA, Ikehara S: Preclinical investigations that subserve efforts to employ bone marrow transplantation for rheumatoid or autoimmune diseases. J Rheumatol Suppl 1997;48:5–12.
48.
Hisha N, Nishino T, Kawamura M, Adachi S, Ikehara S: Successful bone marrow transplantation by bone grafts in chimeric-resistant combination. Exp Hematol 1995;23:347–352.
49.
Ishida T, Inaba M, Hisha H, Sugiura K, Adachi Y, Nagata N, Ogawa R, Good RA, Ikehara S: Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation: Complete prevention of recurrence of autoimmune diseases in MRL/MP-lpr/lpr mice by transplantation of bone marrow plus bone (stromal cells) from the same donor. J Immunol 1994;152:3119–3127.
50.
Hosaka N, Nose M, Kyogoku M, Nagata N, Miyashima S, Good RA, Ikehara S: Thymus transplantation: A critical factor for correction of autoimmune disease in aging MRL/+ mice. Proc Natl Acad Sci USA 1996;93:8558–8562.
51.
Yasumizu R, Sugiura K, Iwai H, Inaba M, Makino S, Ida T, Imura H, Hamashima Y, Good RA, Ikehara S: Treatment of type 1 diabetes mellitus in non-obese diabetic mice by transplantation of allogeneic bone marrow and pancreatic tissue. Proc Natl Acad Sci USA 1987;84:6555–6557.
52.
Ikehara S, Ohtsuki H, Good RA, Asamoto H, Nakamura T, Sekita K, Muso E, Tochino Y, Ida T, Kuzuya H, Imura H, Hamashima Y: Prevention of type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 1985;82:7743–7747.
53.
Wyatt DT, Lum L, Casper J, Hunter J, Camitta B: Autoimmune thyroiditis after bone marrow transplantation. Bone Marrow Transplant 1990;5:357–361.
54.
Mizutani H, Engelman RW, Kurata Y, Ikehara S, Good RA: Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW × BXSB)F1 mice. Blood 1993;82:837–844.
55.
Hang L, Stephen-Larson PM, Henry JP, Dixon FJ: Transfer of renovascular hypertension and coronary heart disease by lymphoid cells from SLE-prone mice. Am J Pathol 1984;115:42–46.
56.
Ikehara S, Inaba M, Ishida S, Ogata H, Hisha H, Yasumizu R, Oyaizu N, Sugiura K, Toki J, Takao F, Than S, Kawamura M, Nishioka N, Nagata N, Good RA: Rationale for transplantation of both allogeneic bone marrow and stromal cells in the treatment of autoimmune diseases; in Champlin RE, Gale RP (eds): New Strategies in Bone Marrow Transplantation. New York, Wiley-Liss, 1991, pp 251–257.
57.
Ikehara S, Yasumizu R, Inaba M, Izui S, Jayakawa K, Sekita K, Toki J, Sugiura K, Iwai H, Nakamura T, Muso E, Hamashima Y, Good RA: Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 1989;86:3306–3310.
58.
Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST: Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994;84:2436–2446.
59.
El-Badri NS, Wang BY, Cherry, Good RA: Osteoblasts promote engraftment of allogeneic hematopoietic stem cells. Exp Hematol 1998;26:110–116.
60.
Good RA: Organization and development of the immune system: Relation to its reconstruction. Ann NY Acad Sci 1995;770:8–31.
61.
Main JM, Prehn RT: Successful skin homografts after the administration of high dosage X-radiation and homologous bone marrow. J Natl Cancer Inst 1955;15:1023–1029.
62.
Coico R, Krown SE, Good RA, Hoffmann MK: Helper cell factors restore antibody responses of allogeneic bone marrow chimeras: Evidence for ineffective cellular interactions. J Immunol 1982;128:1590–1593.
63.
Onoé K, Fernandes G, Shen FW, Good RA: Sequential changes of thymocyte surface antigens with presence or absence of graft-vs-host reaction following allogeneic bone marrow transplantation. Cell Immunol 1982;68:207–219.
64.
Owen RD: Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945;102:400–401.
65.
Anderson D, Billingham RE, Lampkin GH, Medawar PB: The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. Heredity 1952;5:379–397.
66.
Billingham RE, Brent L, Medawar PB: Actively acquired tolerance of foreign cells. Nature 1953;172:603–606.
67.
Martinez C, Shapiro F, Kelman H, Onstad T, Good RA: Tolerance of F1 hybrid skin homografts in the parent strain induced by parabiosis. Proc Soc Exp Biol Med 1960;103:266–269.
68.
Martinez C, Shapiro F, Good RA: Essential duration of parabiosis and development of tolerance to skin homografts in mice. Proc Soc Exp Biol Med 1960;104:256–259.
69.
Onoé K, Good RA, Yamamoto K: Anti-bacterial immunity to Listeria monocytogenes in allogeneic bone marrow chimera in mice. J Immunol 1986;136:4264–4269.
70.
Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH: Characterization of mixed allogeneic chimeras: Immunocompetence, in vitro reactivity and genetic specificity of tolerance. J Exp Med 1985;162:231–244.
71.
Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH: Effects of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft versus host disease in mixed allogeneic chimeras (B10 + B10.D2 → B6). J Immunol 1986;136:28–33.
72.
El-Badri N, Good RA: Induction of immunological tolerance in full major and multiminor histocompatibility-disparate mice using a mixed bone marrow transplantation model. Proc Soc Exp Biol 1994;205:67–74.
73.
Ogata H, Bradley WG, Inaba M, Ogata N, Ikehara S, Good RA: Long-term repopulation of hematolymphoid cells with only a few hemopoietic stem cells in mice. Proc Natl Acad Sci USA 1995;92:5945–5949.
74.
Wang BY, El-Badri NS, Cherry, Good RA: Purified hematopoietic stem cells without facilitating cells can repopulate fully allogeneic recipients across entire major histocompatibility complex transplantation barrier in mice. Proc Natl Acad Sci USA 1997;94:14632–14636.
75.
Ikehara S: Treatment of autoimmune diseases by hematopoietic stem cell transplantation. Exp Hematol 2001;29:661–669.
76.
Wulffraat N, van Royen A, Bierings M, Vossen J, Kuis W: Autologous haemopoietic stem cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 1999;353:550–553.
77.
Burt RK, Traynor AE, Cohen B, Karlin KH, Davis FA, Stefoski D, Terry C, Lobeck L, Russell EJ, Goolsby C, Rosen S, Gordon LI, Keever-Taylor C, Brush M, Fishman M, Burns WH: T cell depeleted autologous hematopoietic stem cell transplantation for multiple sclerosis: Report on the first three patients. Bone Marrow Transplant 1998;21:537–541.
78.
El-Badri NS, Good RA: Lymphopoietic reconstitution using wheat germ agglutinin-positive hemopoietic stem cell transplantation within but not across the major histocompatibility antigen barriers. Proc Natl Acad Sci USA 1993;90:6681–6685.
79.
Prigozhina TB, Gurevitch O, Zhu J, Slavin S: Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues. I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes. Transplantation 1997;63:1394–1399.
80.
Rao SS, Peters SO, Crittenden RB, Stewart FM, Ramshaw HS, Quesenberry PJ: Stem cell transplantation in the normal nonmyeloablated host: Relationship between cell dose, schedule and engraftment. Exp Hematol 1997;25:114–121.
81.
Lowenthal RM, Cohen ML, Atkinson K, Biggs JC: Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol 1993;20:137.
82.
Marmont AM: Immune ablation followed by allogeneic or autologous bone marrow transplantation: A new treatment for severe autoimmune diseases? Stem Cells 1994;12:125–135.
83.
Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM: Pre-existing autoimmune diseases in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl 1997;48:23–29.
84.
Eedy DJ, Burrows D, Bridges JM, Jones FG: Clearance of severe psoriasis after allogeneic bone marrow transplantation. BMJ 1990;300:908.
85.
Ikehara S: Autoimmune diseases as stem cell disorders: Normal stem cell transplant for their treatment. Int J Mol Med 1998;1:5–16.
86.
Sullivan KM, Furst DE: The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. J Rheumatol Suppl 1997;48:1–4.
87.
Burt RK, Traynor AE: Hematopoietic stem cell transplantation: A new therapy for autoimmune disease. Stem Cells 1999;17:366–372.
88.
Giralt S, Khouri I, Champlin R: Non-myeloablative ‘mini transplants’. Cancer Treat Res 1999;101:97–108.
89.
Slavin S: New strategies for bone marrow transplantation. Curr Opin Immunol 2000;12:542–551.
90.
Meislin AG, Rothfield NF: Systemic lupus erythematosus in childhood: Analysis of 42 cases, with comparative data on 200 adult cases followed concurrently. Pediatrics 1968;42:37–49.
91.
Niaudet P: Treatment of lupus nephritis in children. Pediatr Nephrol 2000;14:158–166.
92.
Ikehara S: Pluripotent hemopoietic stem cells in mice and humans. Proc Soc Exp Biol Med 2000;223:149–155.
93.
Taichman RS, Reilly MJ, Emerson SG: Human osteoblasts support human hematopoietic progenitor cells in in vitro bone marrow cultures. Blood 1996;87:518–524.
94.
Taichman RS, Emerson SG: The role of osteoblasts in the hematopoietic microenvironment. Stem Cells 1998;16:7–15.
95.
Haynesworth SE, Baber MA, Caplan AI: Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL-Ia. J Cell Physiol 1996;166:585–592.
96.
Nota JA, Hanley MB, Kohn DB: Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human IL-3:Analysis of gene transduction of long-lived progenitors. Blood 1994;83:3041–3051.
97.
Cahill R, Klemperer M, Steele A, et al: Successful transplantation to correct a metabolic bone disease (infantile hypophosphatasia) using bone fragments plus cultured osteoblasts with T cell depleted mismatched bone marrow without lymphohematopoietic engraftment. Blood 2001;98:1a–1030a [abstract #3314, pp. 796a–797a].
98.
Horowitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309–313.
99.
El-Badri NS, Steele A, Pascual C, Haraguchi S, Marikar Y, Good RA: The role of hematopoietic stem cell transplantation in autoimmune glomerulonephritis. Exp Hematol, in preparation.
100.
Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M: Cell migration, chimerism, and graft acceptance. Lancet 1992;339:1579–1582.
101.
Morita H, Sugiura K, Inaba M, Jin T, Ishikawa J, Lian Z, Adachi Y, Sogo S, Yamanishi K, Taki H, Adachi M, Noumi T, Kamiyama Y, Good RA, Ikehara S: A new strategy for organ allografts without using immunosuppressants and irradiation. Proc Natl Acad Sci USA 1998;95:6947–6952.
102.
Kushida T, Inaba M, Hisha H, Ichioka N, Esumi T, Ogawa R, Iida H, Ikehara S: Intra-bone marrow injection of allogeneic bone marrow cells: A powerful new strategy for treatment of intractable autoimmune disease in MRL/lpr mice. Blood 2001;97:3292–3299.
103.
Jin L, Zeng H, Chien S, Otto KG, Richard RE, Emery DW, Blau CA: In vivo selection using a cell-growth switch. Nat Genet 2000;26:64–66.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.